The Claim
In patients with heart failure with reduced ejection fraction (LVEF ≤40%), type 2 diabetes, or prediabetes, daily treatment with 10 mg of empagliflozin for 36 weeks significantly reduces epicardial adipose tissue volume by 3.4 mL (95% CI -6.7 to -0.1; p=0.045) compared to placebo, as measured by cardiovascular magnetic resonance imaging.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with heart failure and reduced heart pumping ability, with either type 2 diabetes or prediabetes, taking 10 mg of empagliflozin daily for 36 weeks reduces the volume of fat around the heart by 3.4 milliliters compared to a placebo, as measured by cardiac MRI.
See the scientific wording
In patients with heart failure with reduced ejection fraction (LVEF ≤40%), type 2 diabetes, or prediabetes, daily treatment with 10 mg of empagliflozin for 36 weeks significantly reduces epicardial adipose tissue volume by 3.4 mL (95% CI -6.7 to -0.1; p=0.045) compared to placebo, as measured by cardiovascular magnetic resonance imaging, suggesting a direct metabolic effect of SGLT2 inhibition on pericardial fat accumulation.
The drug blocks a protein that reabsorbs sugar in the kidneys, causing the body to burn more fat for energy instead of storing it, which reduces the amount of fat around the heart.
What the research says
1 studyIn people with heart failure and diabetes or prediabetes, taking empagliflozin for 36 weeks led to a small but measurable drop in the fat around the heart, compared to those who took a dummy pill. This suggests the drug may help reduce this harmful fat.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.